ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 3921-3928

  De Iudicibus, Sara ^a   De Pellegrin, Alessandro ^b   Stocco, Gabriele ^a   Bartoli, Fiora ^a   Bussani, Rossana ^b   Decorti, Giuliana ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

ABCB1 gene; Colon cancer; Immunohistochemistry; P glycoprotein; Polymorphisms

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; CANCER RELAPSE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149160026     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Schmoll HJ and Sargent D: Single agent fluorouracil for firstline treatment of advanced colorectal cancer as standard? Lancet 370: 105-107, 2007.
2. Houlston RS and Tomlinson IP: Polymorphisms and colorectal tumor risk. Gastroenterology 121: 282-301, 2001.
3. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, Hofstra RM and Kleibeuker JH: Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11: 1332-1352, 2002.
4. Potocnik U, Glavac MR, Golouh R and Glavac D: The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer. Pflugers Arch 442: R182-R183, 2001.
5. Potocnik U, Ravnik-Glavac M and Glavac D: Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability. Cell Mol Biol Lett 7: 92-95, 2002.
6. Potocnik U, Ravnik-Glavac M, Golouh R and Glavac D: Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet 39: 340-346, 2002.
7. Choudhuri S and Klaassen CD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25: 231-259, 2006.
8. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287, 1990.
9. Johnstone RW, Ruefli AA and Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25: 1-6, 2000.
10. Johnstone RW, Ruefli AA, Tainton KM and Smyth MJ: A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 38: 1-11, 2000.
11. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB and Coon JS: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
12. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, Tsuruo T, Sumizawa T and Akiyama S: Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst 82: 1679-1683, 1990.
13. Hoffmeyer S, Burk O, vonRichter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M and Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
14. Sakaeda T: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20: 391-414, 2005.
15. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB and Telenti A: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30-36, 2002.
16. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK and Cascorbi I: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72: 572-583, 2002.
17. Eichelbaum M, Fromm MF and Schwab M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26: 180-185, 2004.
18. Bonin S, Petrera F, Niccolini B and Stanta G: PCR analysis in archival postmortem tissues. Mol Pathol 56: 184-186, 2003.
19. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U and Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69: 169-174, 2001.
20. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP and Strieker BH: MDR1 gene polymorphisms are associated with neuropsychiatrie adverse effects of mefloquine. Clin Pharmacol Ther 80: 367-374, 2006.
21. Osswald E, Johne A, Laschinski G, Arjomand-Nahad F, Malzahn U, Kirchheiner J, Gerloff T, Meisel C, Mrozikiewicz PM, Chernov J, Roots I and Kopke K: Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 63: 9-16, 2007.
22. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Mild I, Tamura T, Aoyama N, Kasuga M and Okumura K: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21: 126-132, 2006.
23. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W and Lubinski J: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61: 389-394, 2005.
24. Humeny A, Rodel F, Rodel C, Sauer R, Fuzesi L, Becker C and Efferth T: MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 23: 2735-2740, 2003.
25. Koyama T, Nakamura T, Komoto C, Sakaeda T, Taniguchi M, Okamura N, Tamura T, Aoyama N, Kamigaki T, Kuroda Y, Kasuga M, Kadoyama K and Okumura K: MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull 29: 1449-1453, 2006.
26. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K and Kuwano M: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6: 2401-2407, 2000.
27. Goff BA, Ries JA, Els LP, Coltrera MD and Gown AM: Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 70: 378-385, 1998.
28. Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF and Moore MJ: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4: 559-565, 1998.
29. Yeh KH, Chen CL, Shun CT, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL: Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. J Clin Gastroenterol 26: 274-278, 1998.
30. Ralhan R, Swain RK, Agarwal S, Kaur J, Nath N, Sarkar G, Mathur M and Shukla NK: P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 84: 80-85, 1999.
31. Pirker R, Wallner J, Gsur A, Gotzl M, Zochbauer S, Scheithauer W and Depisch D: MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 68: 691-694, 1993.
32. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K and Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer. Cancer 71: 2454-2460, 1993.
33. Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ and Safa AR: Relationship of p-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion. DNA ploidy, and disease relapse. Cancer 74: 2908-2917, 1994.
34. Zorzos HS, Lazaris AC, Korkolopoulou PA, Kavantzas NG, Tseleni-Balafouta S, Patsouris ES, Tsavaris NV and Davaris PS: Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential. Pathology 35: 315-318, 2003.
35. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A and Ohsumi K: Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep 8: 815-819, 2001.
36. Faivre J, Lemmens VE, Quipourt V and Bouvier AM: Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer 43: 2279-2284, 2007.